Some of our Favourites from 2021 – Happy New Year!
Posted on December 28, 2021
We are nearing the end of 2021 and we look forward to bringing you more of the very best from the medical literature on anti-NMDA receptor encephalitis and autoimmune encephalitis in 2022. We hope you have found our weekly selections of value.
Before closing the year, we thought we would share with you some of our favourites and ones we consider important articles from 2021. This was a daunting task as there has been so much valuable literature. We are pleased to share with you our picks of eleven articles from 2021, chosen from our newsletters.
Thank you for supporting our efforts. And, of course, if you wish to make a year-end contribution, (Canadians will receive a tax-deductible receipt) you still have time until midnight, 31 December 2021.DONATE
HAPPY NEW YEAR 2022!
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis
Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis
Rituximab Treatment and Long-term Outcome of Patients with Autoimmune Encephalitis
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis
Neural Antibody Testing for Autoimmune Encephalitis: A Canadian Single-Centre Experience
Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis
Long-Term Cognitive Outcome in Anti–N-Methyl-D-Aspartate Receptor Encephalitis
Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis
The Need for Comprehensive Care
ExTINGUISH Trial Announcement